Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Celldex Therapeutics, Inc., Azenta or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Celldex Therapeutics, Inc., Azenta and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Celldex Therapeutics, Inc., Azenta and Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Latest Biotechnology and Celldex Therapeutics, Inc., Azenta, Inc. Stock News

As of September 1, 2026, Celldex Therapeutics, Inc. had a $3.1 billion market capitalization, compared to the Biotechnology median of $282.5 million. Celldex Therapeutics, Inc.’s stock is up 45.4% in 2026, down 2.7% in the previous five trading days and up 77.72% in the past year.

Currently, Celldex Therapeutics, Inc. does not have a price-earnings ratio. Celldex Therapeutics, Inc.’s trailing 12-month revenue is $0.2 million with a % net profit margin. As of September 1, 2026, Celldex Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.106 per share for the current fiscal year. Celldex Therapeutics, Inc. does not currently pay a dividend.

As of September 1, 2026, Azenta, Inc. had a $1.4 billion market cap, putting it in the 49th percentile of all stocks. Azenta, Inc.’s stock is down 4.6% in 2026, down 5.5% in the previous five trading days and up 3.37% in the past year.

Currently, Azenta, Inc. does not have a price-earnings ratio. Azenta, Inc.’s trailing 12-month revenue is $613.8 million with a -20.0% net profit margin. Year-over-year quarterly sales growth most recently was 12.0%. Analysts expect adjusted earnings to reach $0.375 per share for the current fiscal year. Azenta, Inc. does not currently pay a dividend.

How We Compare Celldex Therapeutics, Inc., Azenta and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Celldex Therapeutics, Inc., Azenta and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Celldex Therapeutics, Inc., Azenta and Inc. Growth Grades

Company	Ticker	Growth
Celldex Therapeutics, Inc.	CLDX	F
Azenta, Inc.	AZTA	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Celldex Therapeutics, Inc. has a Growth Score of 3, which is Very Weak. Azenta, Inc. has a Growth Score of 60, which is Average.

The Growth Stock Winner: No Clear Winner

Neither Celldex Therapeutics, Inc., Azenta or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Celldex Therapeutics, Inc., Azenta or Inc. is the better investment when it comes to sustainable growth.

Celldex Therapeutics, Inc., Azenta and Inc.’s Momentum Grades

Company	Ticker	Momentum
Celldex Therapeutics, Inc.	CLDX	A
Azenta, Inc.	AZTA	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Celldex Therapeutics, Inc. has a Momentum Score of 89, which is Very Strong. Azenta, Inc. has a Momentum Score of 72, which is Strong.

The Momentum Grade Winner: Celldex Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Celldex Therapeutics, Inc. is considered to have stronger momentum compared to Azenta, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Celldex Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Celldex Therapeutics, Inc., Azenta and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Celldex Therapeutics, Inc.	CLDX	C
Azenta, Inc.	AZTA	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Celldex Therapeutics, Inc. has a Earnings Estimate Score of 59, which is Neutral. Azenta, Inc. has a Earnings Estimate Score of 33, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Celldex Therapeutics, Inc., Azenta or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Celldex Therapeutics, Inc., Azenta or Inc. is the better investment when it comes to estimate revisions.

Other Celldex Therapeutics, Inc., Azenta and Inc. Grades

In addition to Momentum, Estimate Revisions and Growth, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Celldex Therapeutics, Inc., Azenta and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Celldex Therapeutics, Inc., Azenta or Inc. Stock?

Overall, Celldex Therapeutics, Inc. stock has a Growth Score of 3, Momentum Score of 89 and Estimate Revisions Score of 59.

Azenta, Inc. stock has a Growth Score of 60, Momentum Score of 72 and Estimate Revisions Score of 33.

Comparing Celldex Therapeutics, Inc., Azenta and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.